3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
13
Rectal Neoplasms
4
Neoplasm Metastasis
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumors
2
Stomach Neoplasms
1
Solid Tumor Cancer
1
Sarcoma, Ewing
1
Sarcoma
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Microsatellite-stable Colorectal Cancer
1
Metastatic Gastric Adenocarcinoma
1
Lung Neoplasms
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Endometrial Neoplasms
1
Desmoid Tumors
1
Craniopharyngioma
1
Colorectal Cancer Metastatic
1
Breast Neoplasms
1
Anal Cancer Metastatic
1
Advanced Microsatellite Stable Colorectal Cancer
1
Adenomatous Polyposis Coli
1
Interventions
pembrolizumab
52
Paclitaxel
19
Cisplatin
14
Carboplatin
14
lenvatinib
10
Docetaxel
8
Saline Solution
7
Capecitabine
7
Pemetrexed
6
Oxaliplatin
6
Gemcitabine
6
Fluorouracil
6
Leucovorin
5
Albumin-Bound Paclitaxel
5
olaparib
4
belzutifan
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
patritumab deruxtecan
3
Glucose
3
Acetaminophen
3
liposomal doxorubicin
2
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Doxorubicin
2
Dexamethasone
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
trifluridine tipiracil drug combination
×
90 days
×
Clear all
NCT05064059
2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3
Completed
441 enrolled
24 charts